Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of nimotuzumab in combination of radio-chemotherapy for the treatment of brainstem tumor in children.


Clinical Trial Description

Nimotuzumab (h-R3), a recombinant humanized monoclonal immunoglobulin G1 antibody that binds to the extracellular domain of EGFR, which blocks the binding of EGF and transforming growth factor-α to EGFR. High expression of EGFR protein in glioma has been associated with tumor progression and enhanced tumorigenicity. Several clinical trials have demonstrated the anti-tumor effects of nimotuzumab, such as head and neck cancer and esophageal cancer15. The purpose of this study was to evaluate the efficacy of nimotuzumab in combination of radio-chemotherapy for the treatment of brainstem tumors in children. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02672241
Study type Interventional
Source Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Contact chuanying zhu, MD
Phone 862125076994
Email sdnanhai123@163.com
Status Recruiting
Phase Phase 2
Start date January 2016
Completion date August 2019